TY - JOUR
T1 - Reappraisal of Total Pancreatectomy in 45 Patients with Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis
T2 - Multicenter Study Group of Pancreatobiliary Surgery in Japan
AU - Satoi, Sohei
AU - Murakami, Yoshiaki
AU - Motoi, Fuyuhiko
AU - Sho, Masayuki
AU - Matsumoto, Ippei
AU - Uemura, Kenichiro
AU - Kawai, Manabu
AU - Kurata, Masanao
AU - Yanagimoto, Hiroaki
AU - Yamamoto, Tomohisa
AU - Mizuma, Masamichi
AU - Unno, Michiaki
AU - Kinoshita, Shoichi
AU - Akahori, Takahiro
AU - Shinzeki, Makoto
AU - Fukumoto, Takumi
AU - Hashimoto, Yasushi
AU - Hirono, Seiko
AU - Yamaue, Hiroki
AU - Honda, Goro
AU - Kwon, Masanori
N1 - Publisher Copyright:
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Objective The aim of this study was to reappraise the clinical role of total pancreatectomy with curative intent in patients with pancreatic ductal adenocarcinoma (PDAC). Methods In 2001 to 2011 database from 7 institutions in Japan, 45 (3.1%) of 1451 patients with PDAC underwent total pancreatectomy (TP group), and 885 patients underwent pancreaticoduodenectomy (PD group). A matched-pairs group consisted of 45 patients matched for age, sex, year, resectability status, and neoadjuvant therapy (matched-PD group). Clinicopathological data, overall survival, and disease-free survival were compared between groups. Results Clinical features of the TP group revealed higher-stage disease, greater surgical stress, a higher frequency of lymph node metastasis, and a lower adjuvant chemotherapy completion rate compared with the PD group (P < 0.05). Overall survival and disease-free survival in the TP group were significantly worse than those in the PD group (P < 0.05). Multivariate analysis revealed resectability status, neoadjuvant therapy, blood transfusion, lymph node metastasis, and adjuvant therapy to be significant prognostic factors. No differences in mortality and morbidity rates were observed between the 2 groups. A matched-pairs analysis revealed similar surgical outcomes and overall survival. Conclusions The surgical outcome of total pancreatectomy for patients with PDAC is acceptable. When margin-negative resection is expected, total pancreatectomy should not be abandoned in the modern era.
AB - Objective The aim of this study was to reappraise the clinical role of total pancreatectomy with curative intent in patients with pancreatic ductal adenocarcinoma (PDAC). Methods In 2001 to 2011 database from 7 institutions in Japan, 45 (3.1%) of 1451 patients with PDAC underwent total pancreatectomy (TP group), and 885 patients underwent pancreaticoduodenectomy (PD group). A matched-pairs group consisted of 45 patients matched for age, sex, year, resectability status, and neoadjuvant therapy (matched-PD group). Clinicopathological data, overall survival, and disease-free survival were compared between groups. Results Clinical features of the TP group revealed higher-stage disease, greater surgical stress, a higher frequency of lymph node metastasis, and a lower adjuvant chemotherapy completion rate compared with the PD group (P < 0.05). Overall survival and disease-free survival in the TP group were significantly worse than those in the PD group (P < 0.05). Multivariate analysis revealed resectability status, neoadjuvant therapy, blood transfusion, lymph node metastasis, and adjuvant therapy to be significant prognostic factors. No differences in mortality and morbidity rates were observed between the 2 groups. A matched-pairs analysis revealed similar surgical outcomes and overall survival. Conclusions The surgical outcome of total pancreatectomy for patients with PDAC is acceptable. When margin-negative resection is expected, total pancreatectomy should not be abandoned in the modern era.
KW - matched-pairs analysis
KW - mortality and morbidity
KW - overall survival
KW - pancreatic ductal adenocarcinoma
UR - http://www.scopus.com/inward/record.url?scp=84951335970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951335970&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000000579
DO - 10.1097/MPA.0000000000000579
M3 - Article
C2 - 26692442
AN - SCOPUS:84951335970
SN - 0885-3177
VL - 45
SP - 1003
EP - 1009
JO - Pancreas
JF - Pancreas
IS - 7
ER -